No connection

Search Results

ATAI vs NVCR

ATAI
AtaiBeckley Inc.
BEARISH
Price
$3.69
Market Cap
$1.34B
Sector
Healthcare
AI Confidence
85%
NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ATAI
--
NVCR
--
Forward P/E
ATAI
-7.44
NVCR
-10.44
P/B Ratio
ATAI
6.04
NVCR
4.02
P/S Ratio
ATAI
327.77
NVCR
2.11
EV/EBITDA
ATAI
-9.93
NVCR
-8.77

Profitability

Gross Margin
ATAI
0.0%
NVCR
74.8%
Operating Margin
ATAI
-3588.09%
NVCR
-21.33%
Profit Margin
ATAI
0.0%
NVCR
-20.79%
ROE
ATAI
-389.98%
NVCR
-38.89%
ROA
ATAI
-30.75%
NVCR
-9.06%

Growth

Revenue Growth
ATAI
--
NVCR
8.1%
Earnings Growth
ATAI
--
NVCR
--

Financial Health

Debt/Equity
ATAI
0.02
NVCR
0.73
Current Ratio
ATAI
11.74
NVCR
2.9
Quick Ratio
ATAI
11.49
NVCR
2.51

Dividends

Dividend Yield
ATAI
--
NVCR
--
Payout Ratio
ATAI
0.0%
NVCR
0.0%

AI Verdict

ATAI BEARISH

ATAI's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme operational weakness, and the absence of an Altman Z-Score (with negative profitability and massive losses) raises significant bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a high target price of $13.45, the company exhibits no profitability, negative margins, and a 620.8% YoY EPS decline, with earnings surprises consistently negative. The stock trades at an inflated Price/Sales of 327.77 and a Price/Book of 6.04, suggesting extreme overvaluation relative to fundamentals. Insider selling in the last six months further undermines confidence in management's view of the company's prospects.

Strengths
Analyst consensus is strongly bullish with a $13.45 target price
High market cap ($1.34B) suggests relative scale within biotech
Extremely high 1-year return (+165.5%) indicates strong momentum
Risks
Piotroski F-Score of 1/9 signals severe financial distress and operational failure
Negative ROE (-389.98%) and ROA (-30.75%) indicate deep unprofitability
Operating margin of -3588.09% reflects catastrophic cost inefficiency
NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)

Compare Another Pair

ATAI vs NVCR: Head-to-Head Comparison

This page compares AtaiBeckley Inc. (ATAI) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile